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Abstract
Background: Inhibitors of the HIV-1 Protease currently used in therapeutic protocols, have been
found to inhibit, although at higher concentrations, the HIV-2 encoded enzyme homologue. Similar
to observations in HIV-1 infected individuals, therapeutic failure has also been observed for some
patients infected with HIV-2 as a consequence of the emergence of viral strains resistant to the
anti-retroviral molecules. In order to be able to define the specific mutations in the Protease that
confer loss of susceptibility to Protease Inhibitors, we set up an experimental model system based
in the expression of the viral protein in yeast.
Results : Our results show that the HIV-2 Protease activity kills the yeast cell, and this process
can be abolished by inhibiting the viral enzyme activity. Since this inhibition is dose dependent, IC50
values can be assessed for each anti-retroviral molecule tested. We then defined the susceptibility
of HIV-2 Proteases to Protease Inhibitors by comparing the IC50 values of Proteases from 7 infected
individuals to those of a sensitive wild type laboratory adapted strain.
Conclusion : This functional assay allowed us to show for the first time that the L90M substitution,
present in a primary HIV-2 isolate, modifies the HIV-2 Protease susceptibility to Saquinavir but not
Lopinavir. Developing a strategy based on the proposed yeast expressing system will contribute to
define amino acid substitutions conferring HIV-2 Protease resistance.
Background
Human Immunodeficiency Virus Type 2 (HIV-2), the sec-
ond causative agent of the acquired immunodeficiency
syndrome (AIDS), is mainly present in West Africa, where
it was discovered [1] and spread to Europe, Asia, and the
Americas in a slow but continuous manner. Although the
two types of HIV (1 and 2) share only 40% of their amino
acid sequences, HIV-2 infected individuals in developed
countries are treated with highly active anti retroviral ther-
apy (HAART), following the same therapeutic protocols
that have been defined for HIV-1 infection.
HAART targets two main viral enzyme activities, the
Reverse Transcriptase and the Protease. The drugs inhibit-
ing the Protease competitively bind the substrate binding
site of the enzyme, thus abolishing the proteolytic matu-
ration of the Gag and Gag-pol precursors, resulting in the
production of immature, non infectious particles [2].
Many epidemiological studies on HIV-1 infected individ-
uals have documented that following anti-retroviral treat-
ments a number of resistant isolates emerge causing
therapeutic failure [3]. Resistant HIV-1 Proteases present a
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specific pattern of amino acid substitutions that are cate-
gorized as major or minor mutations [4].
Thus far the analysis of the data obtained from the few
studies of the impact of Protease Inhibitors (PI), on HIV-
2 infected individuals is still not consistent enough to
clearly define the specific amino acid substitutions confer-
ring resistance to these anti retroviral drugs. Nevertheless,
the few reported data establish that i) the natural nucle-
otide polymorphism of the HIV-2 Protease includes
amino acid substitutions that are associated with drug
resistance in HIV-1 [5], and ii) comparison between the
Protease sequences of treated and untreated HIV-2
infected individuals reveals a number of mutations under
some PI-selective pressure such as K7R, V20I/A, I36V,
V46I, I54L/M, V62A/T, V71L, I82F, I84V/L, 90LM, and
L99F [6-8]. In a recent report, where five primary HIV-2
isolates obtained from two different infected individuals
at different time points were tested for PI activity, it has
been shown that neither I36V, V46I nor V71L modified
the susceptibility of HIV-2 Protease to PIs [9]. Results,
obtained from functional test on the ability of those PI to
inhibit viral replication showed that amino acid substitu-
tions such as : T12P [10], G17Q [10], R72A [10], M76V
[10], I54M [7,9], I82F [7-9], V47A [9], K45R [9] confer a
resistant phenotype.
In this study we present a novel test to assess isolated Pro-
tease susceptibility to PIs. This assay is based on the
expression of the viral Protease in yeast cells and the defi-
nition of IC50 values for the PIs. As a proof of principle for
this assay, we report the susceptibility pattern to Lopinavir
and Saquinavir of HIV-2 Proteases from 7 infected indi-
viduals.
Results
With the aim of designing a tool capable of defining the
susceptibility of any viral Protease from HIV-2 treated or
untreated infected individuals to different PIs in a cellular
context, we exploited the yeast cell. Indeed Saccharomyces
cerevisiae has been used for many decades as an experi-
mental tool to study the functional role of several bacte-
rial and viral proteins through the phenotype of the
resulting transformed cells. Moreover, it has recently been
shown that the HIV-1 Protease expressed in yeast induces
cell lysis by a yet unknown mechanism unrelated to apop-
tosis [11].
The proteases encoded by the two HIV types are not iden-
tical, neither in their amino acid sequence nor in the spe-
cificity of peptide bond recognition [12]. Furthermore
since there is no information concerning the cellular
molecular pathway involved in the HIV protease-specific
lysis of yeast cells, we first tested the phenotype induced
by the expression of the HIV-2 Protease in yeast trans-
formed cells. For this purpose we sub-cloned the Protease
gene of the ROD isolate of HIV-2 in the pRS316Gal1/10
vector [13] under the control of the galactose inducible
Gal 1/10 promoter [14], as detailed in the Material and
Methods section.
HIV-2ROD Protease transformed yeast grew on glucose
containing plates, but not on a galactose carbon source
(Fig 1A). When an HIV specific protease inhibitor, such as
Saquinavir (SQV) at 200 μM concentration, was added to
the culture media (Fig 1A), the lethal phenotype was no
longer observed on galactose. The galactose induced cell
death was found to be directly linked to the protease
enzyme activity, since when the Asp residue of the active
site of the viral enzyme was modified to Ala (D25A
mutant), the inactive Protease expressed in transformed
cells (Fig 1C, lane 3) did not induce cell death when
grown on galactose (Fig 1B). This implies that the pro-
HIV-2 Protease expression in yeast induces cell growtharrest Figure 1
HIV-2 Protease expression in yeast induces cell growthar-
rest. A) BY4741 cells transformed either with pRS316Gal1/
10 (1), pRS316Gal1/10-HIV2PR (2) or pRS316Gal1/10-
HIV2PR-D25A were plated on minimal selective media con-
taining glucose and replica-plated on galactose containing 
media in the presence or the absence of 200 μM Saquinavir. 
Yeast patches were observed after 2 days incubation at 
30°C. B) 0.25 OD600 of yeast cells transformed either with 
HIV-2ROD Protease (wt), or with a genetically inactivated ver-
sion of HIV-2ROD Protease (D25A), were incubated in 5 ml of 
liquid SGalC-Ura for 60 hours. At defined time points cell 
growth was measured (OD600). C) Soluble yeast cell extracts 
obtained from 1OD600 of growing cells were run on a SDS 
17% PAGE, and subjected to Western blot analysis. 1: 
BY4741 [pRS316Gal1/10-HIV2PR] grown in glucose, 2: 25 ng 
of purified recombinant HIV-2 PR [34], 3: BY4741 
[pRS316Gal1/10-HIV2PR(D25A)] grown in galactose, 4 : 
BY4741 [pRS316Gal1/10-HIV2PR] grown in galactose in the 
presence of 60 μM LPV.
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tease activity was responsible for cell death. Additional
evidence supporting that it is indeed this viral enzymatic
activity which kills the yeast cells, and not simply the pro-
duction of the exogenous protein, was provided through
the analysis of the expression of HIV-2ROD Protease in
transformed yeast which grew in galactose in the presence
of 60 μM of the protease inhibitor Lopinavir (LPV). West-
ern Blot analysis of cytoplasmic protein extracts from
those cells showed an 11 Kd band recognized specifically
by a monoclonal antibody raised against the viral Pro-
tease (Fig 1C, lane 2). As expected, this band was absent
when the transformant was grown in glucose (Fig 1C, lane
1).
Based on this observation, we further studied the suscep-
tibility of the Protease from the ROD isolate to LPV and
SQV. Equal amounts of transformed cells were incubated
in galactose, in the presence of increasing amounts of LPV
or SQV. Cell growth was scored 48 h later by measuring
the absorbance of the cell culture at 600nm. There was a
tight correlation observed between the inhibitor concen-
tration and cell growth which allowed determination of
the corresponding IC50 values, for LPV 16.6+/-2.5 μM, and
for SQV 149.7+/-7.2 μM (Fig 2A). These IC50 values were
defined as the inhibitor concentration where cell growth
reached 50% of regular growth in glucose. The growth
arrest was not due to a toxic action of the PIs on the cells,
since pRS316Gal1/10-HIV2PR transformed yeast incu-
bated in glucose, in the presence or the absence of each PI
(Fig 2B), or cells containing the pRS316Gal1/10 plasmid
incubated in galactose, in the presence or the absence of
PI (data not shown) grew identically.
As a first approach to validate this experimental system we
measured the ability of LPV and SQV to inhibit HIV-2ROD
Proteases harbouring resistant mutations. Out of a library
of mutated HIV-2ROD Proteases that we created (see Mate-
rial and Methods), we were able to select 3 mutants, con-
taining at least one of the 8 amino acid substitutions
which were previously defined on clinical samples
through functional studies as conferring resistance [7-10].
The susceptibility to LPV and/or SQV of those mutants
was defined by measuring cell growth of transformed cells
in galactose, in the presence of either 150 μM of LPV or
1mM of SQV, that corresponds respectively to 9.0 and 6.7
fold of the IC50 value of the wild type Protease. In these
culture conditions, cell growth of HIV-2ROD  Protease
transformed yeast was lower when compared to cell
growth in the control media containing glucose. The per-
centage of cell growth was 91.5% in the presence of LPV,
and 75% when incubated with SQV (Table 1). When this
HIV-2ROD  Protease harbours amino acid substitutions
known to be involved in HIV-2 PI resistance such as K45R,
I54M, or M76V [9,10], cell growth, in spite of the presence
of the inhibitors, was strongly arrested achieving in some
cases only 4% of normal growth (Table 1) demonstrating
a tight correlation between resistance, defined in physio-
logical conditions, and loss of susceptibility, defined in
our experimental system.
Using this assay, the susceptibility of HIV-2 Proteases
from infected individuals was determined. We amplified
the protease from DNA extracted from peripheral blood
lymphocytes from 7 infected individuals either undergo-
ing successful antiretroviral treatment or experiencing
treatment failure (Table 2), as described in Material and
Methods. For correct expression in yeast, an ATG start
codon was introduced before the first Protease amino
acid, and a TAA stop codon preceded by a Leu codon (as
in HIV-2ROD  Protease) was introduced after the 98th
codon. The DNA fragments obtained were sub cloned into
the pRS316Gal1/10 expression vector, and the resulting
plasmids were used to transform BY4741 yeast cells. Yeast
transformants expressing HIV-2 Proteases were tested for
their ability to grow in galactose in the presence of LPV
and SQV (Table 3). We observed that at a concentration of
150 μM of LPV, one yeast strain presented cell growth sim-
ilar to the ROD isolate (expressing MRT-29 viral Pro-
tease), three presented cell growth comparable to growth
observed in glucose containing media (expressing MRT-7,
-22, -25 viral Proteases), two (expressing MRT-8, -20 viral
Proteases) showed a slightly lower growth than the ROD
isolate, and only the yeast transformant expressing the
MRT-1 Protease was impaired in its growth. When the
same transformed cells were incubated in the presence of
1mM SQV, four of them showed the same phenotype as
the ROD isolate (MRT-1, -20, -22, -29), two showed a cell
growth comparable to the one obtained in glucose con-
Susceptibility of HIV-2ROD Protease to Protease Inhibitors in  transformed yeast 0.02 OD600/well of BY4741 [pRS316Gal1/ 10-HIV2PR] cells were either incubated in Galactose (A) or  Glucose (B) containing synthetic media in the presence of  increasing amounts of LPV and SQV (from 1.5 μM to 200  μM) in a 96 well plate Figure 2
Susceptibility of HIV-2ROD Protease to Protease Inhibitors in 
transformed yeast 0.02 OD600/well of BY4741 [pRS316Gal1/
10-HIV2PR] cells were either incubated in Galactose (A) or 
Glucose (B) containing synthetic media in the presence of 
increasing amounts of LPV and SQV (from 1.5 μM to 200 
μM) in a 96 well plate. After 48 h at 30°C cellular growth was 
determined by measuring cell density at 600nm and plotted 
against PI concentrations. Results are presented as the per-
centage of cell growth; [(OD600 cells grew in Galactose with 
PI – OD600 cells grew in Galactose)/OD600cells grew in Glu-
cose] × 100.
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taining media (MRT-7, -25), and only yeast transformant
containing the MRT-8 Protease grew to 55% compared to
the control (Table 3). We further defined the IC50 values
of the viral enzyme activity from those patients (Table 3).
Interestingly, among the different samples analysed, only
MRT-8 presented an IC50 to SQV 4.2 fold greater than the
reference strain. Although definition of specific sensitive/
resistant cut-off values (IC50 patient isolate/IC50 sensitive-
strain) for each PI can only be obtained after a clinical
study, the IC50 ratio we found for MRT-8 expressing Pro-
tease correlates to reported findings where loss of sensitiv-
ity corresponded to a higher IC50 value of about 4 fold,
compared to the sensitive wild type isolate [15]. It should
be remarked that :i) the HIV-2 Protease isolated from
patient MRT-25 who never received SQV, showed a hyper-
sensitivity towards this inhibitor (IC50MRT-25/IC50HIV-
2ROD = 0.03), and ii) the Protease from patient MRT-1
showed a loss in sensitivity to LPV which might not be
related to resistance since the IC50 ratio was found to be
lower than 4.
In an attempt to define the amino acid mutation/s specif-
ically responsible/s for the SQV loss of sensitivity pheno-
type of the MRT-8 Protease, we sequenced the coding
DNAs of the 7 different Proteases and compared the
sequences obtained to that of HIV-2ROD Protease (Fig. 3).
Among the 9 mutations observed in the MRT-8 Protease
(4 conservative and 5 non-conservative), we focused on
the 90th residue since the L90M substitution has already
been classified as a major mutation in HIV-1 which con-
fers resistance to SQV and LPV [4], and has been suggested
to be associated with resistance to a yet undefined PI in
HIV-2 Protease [8,16]. The HIV-2ROD  Protease was
mutated and the resultant ROD L90M mutant was tested
for its susceptibility to LPV and SQV in yeast as was per-
formed for HIV-2 Proteases from infected individuals. At
the same time we created and tested the ROD L99F
mutant, since this mutation was proposed to confer PI
resistance in a study that scored the emergence of muta-
tions in infected individuals failing an anti-protease con-
taining regime [6], and no functional data of this
suggested resistance is available. The results obtained, pre-
sented in Table 4, show that the L90M mutant have lost
sensitivity to SQV but not to LPV (IC50HIV-2ROD L90M/
IC50HIV-2RODwt = 3.7 and 0.75 respectively). Conversely,
the Phe residue in position 99 did not modify the
Table 2: Protease Inhibitor treatment received by HIV-2 infected individuals
Patient Protease Inhibitor CD4 (cells/μl) Viral load (Log10) Therapeutic failure
MRT-1 NFV 173 3.9 yes
MRT-7 RTV, NFV 335 4.5 yes
MRT-8 SQV, IDV/rtv, NFV 211 5.3 yes
MRT-20 IDV, NFV 229 2 no
MRT-22 NFV, LPV 106 3.9 yes
MRT-25 IDV, LPV/rtv, APV/rtv 82 3.9 yes
MRT-29 NFV 53 4.5 yes
The Protease Inhibitors sequentially received by each patient from a previous cohort [6] are listed. (For this study, blood samples were taken on 
April 2002 for MRT-1, March 2002 for MRT-7, June 2003 for MRT-8, December 2000 for MRT-20, June 2002 for MRT-22, February 2003 for MRT-
25, and May 2002 for MRT-29). Therapeutic failure was defined when the CD4 counts were < 200 and/or the viral load remained unchanged after 
treatment [6].
Table 1: Protease Inhibitor resistance of HIV-2 Proteases tested in yeast
HIV-2ROD sequence Phenotype (virus production) Phenotype (transformed yeast) (% cell growth)
LPV SQV LPV SQV
wild type SS 91.5+/-1.2 75.0+/-7.0
K45R R [9] R [9] 50.3+/-3.0 39.0+/-4.3
V20A, I54M R [9] R [9] 17.1+/-0.7 25.7+/-0.8
M76V n.d. R [10] 0.0+/- 2.4 4.0+/-0.2
The susceptibility of mutated HIV-2ROD Proteases, harbouring amino acid substitutions known to confer a resistant phenotype, were assessed in 
yeast in the presence of LPV at 150 μM and SQV at 1mM.
The resistant (R) or sensitive (S) phenotype is referred to previously published data.
Results in the yeast system are presented as the percentage of cell growth; [(OD600 cells grew in Galactose with PI – OD600 cells grew in 
Galactose)/OD600 cells grew in Glucose] × 100.Retrovirology 2006, 3:58 http://www.retrovirology.com/content/3/1/58
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respondent character of the Protease to either of the tested
PIs (IC50HIV-2ROD L99F/IC50HIV-2RODwt = 0.67 for LPV
and 0.98 for SQV).
Through the data presented we have showed that the loss
of HIV-2 Protease sensitivity to LPV and SQV can easily be
evaluated by defining the IC50on protease-expressing
yeast cells. Developing similar strategies to measure the
IC50 values for other PIs in yeast constitutes the next step
necessary to clearly define the overall resistance pheno-
type of any HIV-2 Protease.
Amino acid sequences of Proteases from HIV-2 infecting isolates Figure 3
Amino acid sequences of Proteases from HIV-2 infecting isolates. PCR amplified HIV-2 Protease coding regions from 7 infected 
individuals were sequenced as described in Material and Methods and translated to amino acid sequence. Conservatives amino 
acid substitutions are in green while non-conservatives are in red.
MRT-1 PQFSLWKRPV10 VTAYIEGQPV20 DVLLDTGADD30 SIVAGIELGS40 DYSPKIVGGI50
MRT-7 PQFSLWKRPV10 VTAHIEGQPV20 EVLLDTGADD30 SIVAGIELGN40 NYSPKIVGGI50
MRT-8 PQFSLWKRPV10 VTAYIEDQPV20 DVLLDTGADD30 SIVAGIELGS40 NYTPKIVGGI50
MRT-20 PQFSLWKRPV10 VTAYIEGQPV20 EVLLDTGADD30 SIVAGIELGS40 NYSPKIVGGI50
MRT-22 PQFSLWKRPV10 VTAYIEGQPV20 EVLLDTGADD30 SIVAGIELGS40 NYSPKIVGGI50
MRT-25 PQFSLWKRPV10 VTAHIEGQPV20 EVLLDTGADD30 SIVAGIELGS40 NYSPKIVGGI50
MRT-29 PQFSLLKRPV10 VTAYIEGQPV20 EVLLDTGADD30 SIVAGIELGS40 NYTPKIVGGI50
ROD PQFSLWKRPV10 VTAYIEGQPV20 EVLLDTGADD30 SIVAGIELGN40 NYSPKIVGGI50
MRT-1 GGFINTKEYK60 NAEIKVLNKR70 IRATIMTGDT80 PINIFGRNIL90 TALGMSLNL99
MRT-7 GGFINTKEYK60 NVEIKVLNKK70 VRATIMTGDT80 PINIFGRNIL90 TALGMSLNL99
MRT-8 GGFINTKEYK60 NVEIKVLNKR70 IRATIMTGDT80 PINIFGRNIM90 TTLGMSLNL99     
MRT-20 GGFINTKEYK60 NAEIKVLNKR70 IRATIMTGDT80 PINIFGRNIL90 TALGMSLNF99
MRT-22 GGFINTKEYK60 NAEIEVLNRK70 IRATIMTGDT80 PINIFGRNIL90 TALGMSLNF99     
MRT-25 GGFINTKEYK60 NVEIEVLGKR70 VRATIMTGDT80 PINIFGRNIL90 TALGMSLNL99     
MRT-29 GGFINTKEYK60 NVEIKVLNKR70 VRATIMTGDT80 PINIFGRNIL90 TALGMSLNL99
ROD GGFINTKEYK60 NVEIEVLNKK70 VRATIMTGDT80 PINIFGRNIL90 TALGMSLNL99     
Table 3: Definition of HIV-2 Protease susceptibility to LPV and SQV, from infected individuals
Phenotype (transformed yeast) (% cell 
growth)
IC50 [μM] IC50isolate/IC50ROD
Protease LPV SQV LPV SQV LPV SQV
ROD 91.5+/-1.2 75.0+/-7.0 16.6+/-2.5 149.7+/- 7.2 1.00 1.00
MRT-1 50.0+/-3.0 71.0+/-5 48.0+/-3.2 200.1+/-5.1 2.89 1.34
MRT-7 100.0+/-4.7 98.0+/-6 10.8+/-5.0 68.9+/-6.2 0.72 0.46
MRT-8 82.0+/-7.5 55.0+/-6.3 12.5+/-1.5 553.9+/-4.2 0.66 4.23
MRT-20 71.5+/-1.2 78.0+/-3.0 23.2 +/-4.4 118.0+/-6.3 1.40 0.79
MRT-22 98.5+/-1.0 82.0+/-7.1 15.1+/-4.3 104.8+/-7.1 0.91 0.70
MRT-25 100.0+/-2.0 100.0+/-9.4 19.9+/-4.6 48.5+/-4.7 1.20 0.03
MRT-29 93.0+/-2.0 72.0+/-3.0 13.9+/-5.5 153.1+/-3.0 0.84 1.02
Viral Protease genes from HIV-2 infected individuals, as well as from the ROD isolate, were PCR amplified, sub-cloned in pRS316Gal1/10 
expression vector and used to transform yeast cells. Protease susceptibility to LPV and SQV was determined by defining the % of cell growth in 
galactose in the presence of inhibitors (as in table 1), and IC50 values were defined as in Fig 2A.Retrovirology 2006, 3:58 http://www.retrovirology.com/content/3/1/58
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Discussion
The causal relationship between the increase of the viral
load in plasma and the emergence of HIV isolates that are
resistant to protease inhibitors and other anti retroviral
compounds has been well established for HIV-1 infected
individuals experiencing therapeutic failure [8,17,18]. In
relation to HIV-2 infection, there is still a lack of informa-
tion concerning the amino acid substitutions that confer
resistance to various PIs. Current phenotyping methods
for defining the sensitivity of an isolate to PIs, are founded
on the production of a virus that contains the PCR ampli-
fied gene encoding the Protease isolated from the infected
individual in a wild type genetic backbone [reviewed in
19]. This chimeric virus is then tested for its infectivity in
the presence of PIs, and the IC50 values are obtained. This
technology is complex and requires a significant infra-
structure which is not well adapted for screening an
increasing number of HIV-2 Proteases from infected indi-
viduals. As a way to define the biochemical resistance phe-
notype of viral proteases, we set up a simple and accurate
experimental yeast cellular system to evaluate Protease
sensitivity to antiretroviral compounds.
Our initial observation in this study was that the expres-
sion of the Protease encoded by HIV-2 in yeast cells
induces cell death, as previously shown for the HIV-1
homologue [11]. This is not the only example of viral pro-
teases that arrest cell growth in S. cerevisiae. Previous
reports show that the 2A proteases from poliovirus and
human rhinovirus 2 [20,21], both species belonging to
the Picornavidae genus, produce cell growth arrest leading
to cell death 10 h after their expression in yeast. These
studies did not elucidate the specific protease-induced
molecular cascades involved in cell death, but suggest the
inhibition of RNA synthesis but not of translation as a key
mechanism [20,21]. Although HIV-1 Protease possesses
unique structural and functional properties that distin-
guish it from its cellular aspartic counterparts [22], several
cellular proteins have been found to be efficient sub-
strates. Among those, are proteins of the intermediary fil-
aments, cytoskeleton components such as vimentin,
desmin and glyal fibrillary acidic protein or cytoskeletal
proteins as actin, troponin, tropomyosin [23,24], and
microtubule-associated proteins [25], or bcl-2 [26], and
precursors of NF-κB [27]. Human cells expressing the
HIV-1 Protease die via apoptosis [26], however the lethal
effect of this enzyme activity in yeast is likely to involve
other death pathways since there is no evidence of apop-
tosis in S.cerevisiae [28]. It can thus be hypothesized that
S. cerevisiae cell lysis produced by the viral Protease might
occur through a drastic modification and/or degradation
of the cellular cytoskeleton, as it does in higher eukaryote
cells.
The mechanism by which HIV Proteases induce cell death
in yeast is still an issue to be clarified, however since inhi-
bition of Protease enzyme activity restores cell growth in
HIV-2 Protease transformed yeast cells, we were able to
define the IC50 values of the Protease from HIV-2ROD to
LPV and SQV: 16.6+/-2.5 μM and 149.7+/-7.2 μM respec-
tively. The difference between these values and those
already reported in the literature, 27 nM and 11 nM
respectively [9,29], might come from the nature of the
yeast cell architecture. Indeed, the plasma membrane of
the yeast cell has a non-human lipid composition that
accounts for a different cell permeability. Moreover, the
nature of the yeast cell wall might be a barrier for the entry
of molecules that are hardly soluble in aqueous solutions,
as the PIs.
The novel experimental system we present in this study
allowed us to define the biochemical resistance pheno-
type to LPV and SQV for isolates from HIV-2 infected indi-
viduals either experiencing therapy failure or not.
Moreover for the first time we were able to clearly define
that the L90M substitution is responsible for SQV resist-
ance but does not alter LPV sensitivity.
Our study also points out the importance of defining a PI
susceptibility phenotype, as opposed to relying on the
genotype, for definition of PI resistance/sensitivity in HIV-
2 Protease isolates. The L99F substitution has previously
been proposed to be involved in PI resistance, based on
comparison of HIV-2 Protease sequences from PI
untreated and treated patients [6]. However, in our phe-
notyping system, the L99F substitution did not modify
susceptibility either to LPV or to SQV. This, highlights the
limitations of comparative genotyping procedure in deter-
mining susceptibility of HIV-2 Proteases to PI and in pre-
dicting the ability of a given PI to inhibit isolates
containing particular mutations. Establishing PI suscepti-
bility phenotypes is the most accurate method to deter-
Table 4: Definition of mutated HIV-2RODProtease susceptibility to LPV and SQV
IC50 [μM] IC50mutant/IC50ROD
HIV-2 Protease mutant LPV SQV LPV SQV
L90M 12.5+/-8.1 554.1+/-3.9 0.75 3.70
L99F 11.1+/-3.1 147.2+/-5.1 0.67 0.98
L90M and L99F HIV-2ROD mutated Proteases were expressed in yeast. IC50 values to LPV and SQV were defined as in Fig 2A.Retrovirology 2006, 3:58 http://www.retrovirology.com/content/3/1/58
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mine whether an HIV-2 virus strain is sensitive to a
specific inhibitor used in a therapeutic protocol.
Our work is a proof-of-concept setting up and evaluating
a phenotypic test to define protease susceptibility to PIs
for HIV-2. The next step will include clinical validation to
establish correlations with clinical outcomes and evaluate
the predictive value for therapeutic failure.
Materials and methods
Patients
Patients were selected from a previous cohort of HIV-2
infected individuals being treatedat different hospitals in
Marseilles and the surrounding area [6]. CD4 cell counts
and viral load determination of each sample were assessed
[6].
Nucleic acid extraction and purification
Whole blood was collected in tubes containing EDTA.
Peripheral blood mononuclear cells (PBMC) were sepa-
rated from blood samples collected in EDTA by Ficoll-
Hypaque centrifugation (Eurobio, Les Ullis, France). Aliq-
uots containing 1×106 to 5×106 PBMC measured by cell
count were frozen as dry pellets at -80°C until they were
processed. The PBMC pellets were thawed, and total DNA
was extracted using a QIAamp DNA minikit (Qiagen).
Prepared DNA was directly analyzed or stored at -80°C.
Construction of mutated HIV-2 Protease library
Mutated HIV-2 Proteases were generated by PCR using the
Diversify PCR Random Mutagenesis Kit (BD Biosciences
Clontech) on HIV-2ROD DNA. The amplification reaction
was performed following the manufacturer instructions
with primers BN-3 and NS. The obtained PCR products
were cloned as a mutated library in pRS316Ga-RH plas-
mid through yeast transformation in a one step proce-
dure. pRS316Ga-RH is a NotI linearisation product of
pRS316Ga-RH-HIV2. pRS316Ga-RH-HIV2 is a modifica-
tion of pRS316-Gal1/10 plasmid, where the BamHI-SacI
polylinker region was replaced by the HIV-2ROD Protease
flanked in its 5' extremity by the sequence of oligonucle-
otide BN-3, and in its 3' end by the sequence of the oligo-
nucleotide SN.
BN-3 contains a BamHI and NotI restriction sites, under-
lined, and a start codon, in bold :
CGAGGATCCGGAGACACCATACAGGGAGCCAC-
CAACAGCGGCCGCGCCATGCCTCAATTC. NS contains
a SacI and NotI restriction sites, underlined, and a stop
codon, in bold : GCGGAGCTCGCTTTAGCATTATTTT-
TATTGGCTCTACTGCGGCCGCTTATAGATT.
Subcloning of the PCR products in the expressing vector
was done as follows, in a one step procedure taking
advantage of the homologous recombination event in
yeast. Co-transformation of linear pRS316Ga-RH plasmid
and the PCR mutated library was performed. Transform-
ants living in glucose but dying in galactose in the pres-
ence of either 150 μM LPV or 1mM SQV were selected and
the harboured viral Proteases sequenced.
Viral DNA PCR amplification
Protease and RT genomic regions were amplified in a 50-
μl reaction mixture under the conditions recommended
by the manufacturer. Nested PCR was performed using 1
to 10 μl of purified DNA, 50 pmol of inner primers (for-
ward: H2Mp3, 5'-ACTTACTGCACCTCGAGCA, 2,020 bp;
reverse: H2Mp4, 5'-CCCAAATGACTAGTGCTTCTT, 3,527
bp), to obtain a genomic fragment of 1,507 bp. The PCR
products were analyzed in a 1.5% agarose gel with ethid-
ium bromide.
HIV-2 Proteases
The DNA fragments coding for the different HIV-2 pro-
teases were amplified by PCR, either from HIV-2ROD
clone14 [30] or from the PCR amplified 1507 bp frag-
ment from HIV-2 infected PBMC extracted DNA [6]. The
primers used were : Fwd, CAGAGGATCCGCTATGCCT-
CAATTCTC, that contains a BamHI site followed by a start
(bold underlined) codon 5' to the first amino acid of the
Protease sequence, and Rev, CCGGACTTATAGATTTAAT-
GACATGCC, that contains a stop codon 3' to the last pro-
tease encoded Leu amino acid. The 412 bp length product
was blunt ended, purified by WIZARD PCR Preps DNA
purification kit (PROMEGA), subcloned in pGEM T easy
vector, and further sub-cloned in pRS316GAL1/10 expres-
sion vector [12] as a BamHI-SacI fragment.
The genetically inactivated HIV-2ROD Protease (D25A) was
constructed by 3 consecutive PCR reactions on HIV-2ROD
clone14. The first PCR, produced a DNA fragment coding
for a truncated protease starting at its 14th amino acid and
carrying the D25A mutation. The second PCR added to
the resulted DNA fragment the sequence coding for the
amino acids 8th to 13th. The last PCR added the sequence
coding for the amino acids 1st to 7th, preceded by a start
codon and 5' flanked by a BamHI site. The final amplified
DNA fragment was sub-cloned into pRS316GAL1/10
expression vector following the same procedure as
described for the wt gene. The 3' primer used in all three
reactions was Rev. The different 5' primers were: for the
first PCR : F14-28, ACATTGAGGGTCAGCCAGTA-
GAAGTTTTGTTAGCCACGGGAGC, where the GAC
codon, coding for Asp in position 25, was changed to
GCC (bold underlined) coding for Ala. For the second
PCR: F8-17, AAGACCAGTAGTCACAGCATACATT-
GAGGG. For the third PCR: FB1-9,
CAGAGGATCCGCTATGCCTCAATTCTCTCTTTGGAAAA-
GACCAG.Retrovirology 2006, 3:58 http://www.retrovirology.com/content/3/1/58
Page 8 of 9
(page number not for citation purposes)
All PCR products were purified using the WIZARD PCR
Preps DNA purification kit (PROMEGA).
The L90M mutant was constructed by PCR using the prim-
ers Fwd and 3-90LM. 3-90LM,
CCGGACTTATAGATTTAATGACATGCCTAAGGCTGT-
CATAATATTTCTGCC, contains the Met codon at position
90 (bold underlined) and a stop codon 3' to the last Pro-
tease encoded amino acid. The obtained product was
purified and sub-cloned as a BamHI-SacI fragment in
pRS316GAL1/10.
The L99F HIV-2 Protease was constructed by PCR using
the primers Fwd and pL99F. pL99F, a reverse primer,
CCGGACTTAGAAATTTAATGACATGCC, contains a Phe
codon (bold underlined) at position 99 of the HIV-2 Pro-
tease, followed by a stop codon. The product was purified
and sub-cloned as a BamHI-SacI fragment in
pRS316GAL1/10 expression vector following the same
procedure as for the wild type Protease.
Yeast transformation
Yeast strain BY4741 (MATa, hisΔ 1, leu2Δ 0, met15Δ 0,
ura3Δ 0 ) obtained from EUROSCARF [31] was trans-
formed following the Lithium Acetate procedure [32].
Inhibition of HIV-2 Protease and IC50 determination
BY4741 yeast cells harbouring the DNA encoding the dif-
ferent HIV-2 Proteases were grown overnight at 30°C in
liquid SDC-URA medium to exponential phase. 2.5
OD600nm were harvested and washed twice with sterile
water and re-suspended in 25 ml of SGalC-URA (supple-
mented minimal yeast nitrogen base with galactose
instead of glucose). 0.02 OD600nm were seeded in each
well of a 96 micro-well plate in the presence or absence of
a Protease Inhibitor. The plates were incubated 48h at
30°C and cell growth was estimated by measuring the
optical density at 600 nm with a TECAN Genesis RSP100
(Tecan Inc., Research Triangle Park, N.C). Cell growth, as
% of cells growing in glucose containing media =
[(OD600nm of cells grown in Galacatose and PI containing
media – OD600nm of cells grown in Galacatose)/OD600nm
of cells grown in Glucose] × 100, were plotted against Pro-
tease Inhibitor concentration and the IC50  value was
defined as the inhibitor concentration that rescues 50% of
cell growth. Experiments were performed in triplicate.
Protease inhibitors
The Protease Inhibitors used in this study are a kindly gift
from Abbott Laboratories (for Lopinavir) and from Roche
Diagnostics GmbH, Mannheim, Germany (for Saquina-
vir).
Western blot analysis
10 ml of yeast cell grown to exponential phase were har-
vested, centrifuged and lysed using glass beads in Lae-
mmli buffer as previously described [33]. Solubilized
proteins were resolved on SDS 17% PAGE and transferred
onto nitrocellulose membrane. Immunoblotting was car-
ried on with a mouse monoclonal antibody recognizing
HIV-1 and -2 proteases ab8327 (Abcam), followed by per-
oxydase-conjugated goat anti-mouse antibodies (Jackson
ImmunoResearch). The HIV-2 protease was detected
using the ECL kit (Amersham Biosciences, Upsala, Swe-
den).
DNA sequencing
pRS316Gal1/10 vectors harbouring viral Proteases from
infected individuals were used as DNA template for nucle-
otide sequence with primers GAL (TGCATAACCACTT-
TAACT), hybridising with the 5' upstream region to the
viral gene, and M13F (GTTTTCCCAGTCACGACG)
hybridising with the 3' downstream region to the viral
gene. The protease gene was sequenced in both directions
with the Big dye Terminator version 1.1 cycle sequencing
Ready Reaction PCR kit (PerkinElmer, Coignières,
France). Resulted products were purified on MultiScreen-
PCR Filter Plate (Millipore, Saint-Quentin en Yvelines,
France) and sequenced on an Applied Biosystem auto-
matic sequencer model 3100 (PerkinElmer).
Abbreviations
Lopinavir (LPV), Saquinavir (SQV), Protease Inhibitor
(PI), Highly active anti retroviral therapy (HAART).
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
NBM and GA performed the experiments. PG wrote the
manuscript and participated with NBM and GA in the
experimental design and data interpretation. DR provided
the clinical specimens and participated in data interpreta-
tion. All authors read and approved the final manuscript.
Acknowledgements
Purified HIV-2 recombinant Protease was obtained through the AIDS 
Research and Reference Reagent Program, NIAID, NIH: HIV-2 Protease 
from Bret Shirley and Mr. Michael Cappola, Boehringer Ingelheim Pharma-
ceuticals, Inc. The protease inhibitors used in this study are a kindly gift 
from Abbott Laboratories and from Roche Diagnostics GmbH, Mannheim, 
Germany.
We are deeply indebted to Dr. Denise Naniche for critically reading the 
manuscript. NBM is a recipient of a fellowship from the Ministère de la 
Recherche, France.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Retrovirology 2006, 3:58 http://www.retrovirology.com/content/3/1/58
Page 9 of 9
(page number not for citation purposes)
References
1. Clavel F, Guetard F, Brun-Vezinet F, Chamaret S, Rey MA, Santos-
Ferreira MO, Laurent AG, Dauguet C, Katlama C, Rouzioux C, Klatz-
mann D, Champalimaud JL, Montagnier L: Isolation of a new
Human Retrovirus from West African Patients with AIDS.
Science 1986, 233:343-346.
2. Robins T, Plattner J: HIV protease inhibitors: their anti-HIV
activity and potential role in treatment.  J Acquir Immune Defic
Syndr 1993, 6:162-170.
3. Erickson JW, Burt SK: Structural mechanisms of HIV drug
resistance.  Annu Rev Pharmacol Toxicol 1996, 36:545-571.
4. Johnson VA, Brun-Vézinet F, Clotet B, Conway B, Kuritzkes DR, Pillay
D, Schapiro JM, Telenti A, Richman DD: Update of the drug resist-
ance mutations in HIV-1: Fall 2005.  Top HIV Med 2005,
13:125-31.
5. Pieniazek D, Rayfield M, Hu DJ, Nkengasong JN, Soriano V, Heneine
W, Zeh C, Agwale SM, Wambebe C, Odama L, Wiktor SZ: HIV-2
protease sequences of subtypes A and B harbor multiple
mutations associated with protease inhibitor resistance in
HIV-1.  AIDS 2004, 18:495-502.
6. Colson P, Henry M, Tourres C, Lozachmeur D, Gallais H, Gastaut JA,
Moreau J, Tamalet C: Polymorphism and drug-selected muta-
tions in the protease gene of human immunodeficiency virus
type 2 from patients living in Southern France.  J Clin Microbiol
2004, 42:570-577.
7. Rodes B, Holguín A, Soriano V, Dourana M, Mansinho K, Antunes F,
González-Lahozet J: Emergence of drug resistance mutations
in human immunodeficiency virus type 2-infected subjects
undergoing antiretroviral therapy.  J Clin Microbiol 2000,
38:1370-1374.
8. van der Ende ME, Prins JM, Brinkman K, Keuter M, Veenstra J, Danner
SA, Niesters HG, Osterhaus AD, Schutten M: Clinical, immuno-
logical and virological response to different antiretroviral
regimens in a cohort of HIV-2-infected patients.  AIDS 2003,
17(Suppl 3):S55-61.
9. Rodes B, Sheldon J, Toro C, Jimenez V, Alvarez MA, Soriano V: Sus-
ceptibility to protease inhiitors in HIV-2 primary isolates
from patients failing antiretroviral therapy.  J Antimicrob Chem-
other 2006, 57:709-713.
10. Goncalves J, Coelho S, Antunes F, Moniz-Pereira J: Phenotypic
identification of HIV-2 protease resistance mutations by
recombinant viral assay.  Antivir Therapy 2006, 7:S28.
11. Blanco R, Carrasco L, Ventoso I: Cell killing by HIV-1 protease.  J
Biol Chem 2003, 278:1086-1093.
12. Chou K-C: Prediction of human immunodeficiency virus pro-
tease cleavage sites in proteins.  Anal Biochem 1996, 233:1-14.
13. Liu H, Krizek J, Bretscher A: Construction of a GAL1-regulated
yeast cDNA expression library and its application to the
identification of genes whose overexpression causes lethality
in yeast.  Genetics 1992, 132:665-673.
14. Johnston M, Davis RW: Sequences that regulate the divergent
GAL1-GAL10 promoter in Saccharomyces cerevisiae.  Mol
Cell Biol 1984, 4:1440-1448.
15. Mo H, King MS, King K, Molla A, Brun S, Kempf DJ: Selection of
Resistance in Protease Inhibitor-Experienced, Human
Immunodeficiency Virus Type 1-Infected Subjects Failing
Lopinavir- and Ritonavir-Based Therapy: Mutation Patterns
and Baseline Correlates.  J Virol 2005, 79:3329-3338.
16. Damond F, Brun-Vezinet F, Matheron SG, Peytavin GP, Campa P,
Pueyo S, Mammano F, Lastere S, Farfara I, Simon F, Chene G, Des-
camps D: Polymorphism of the human immunodeficiency
virus type 2 (HIV-2) protease gene and selection of drug
resistance mutations in HIV-2-infected patients treated with
protease inhibitors.  J Clin Microbiol 2005, 43:484-487.
17. Adjé-Touré CA, Cheingsong R, Garcìa-Lerma JG, Eholié S, Borget M,
Bouchez J, Otten RA, Maurice C, Sassan-Morokro M, Ekpini RE,
Nolan M, Chorba T, Heneine W, Nkengasong JN: Antiretroviral
therapy in HIV-2-infected patients: changes in plasma viral
load, CD4+ cell counts, and drug resistance profiles of
patients treated in Abidjan, Cote d'Ivoire.  AIDS 2003,
17(Suppl 3):S49-54.
18. Chew CB, Potter SJ, Wang B, Wang YM, Shaw CO, Dwyer DE, Sak-
sena NK: Assessment of drug resistance mutations in plasma
and peripheral blood mononuclear cells at different plasma
viral loads in patients receiving HAART.  J Clin Virol 2005,
33:206-216.
19. Baldanti F, Paolucci S, Dossena L, Gerna G: Assays for determina-
tion of HIV resistance to antiviral drugs.  Curr Drug Metab 2004,
5:317-319.
20. Barco A, Carrasco L: Poliovirus 2Apro expression inhibits
growth of yeast cells.  FEBS Lett 1995, 371:4-8.
21. Klump H, Auer H, Liebig HD, Kuechler E, Skern T: Proteolytically
active 2A proteinase of human rhinovirus 2 is toxic for Sac-
charomyces cerevisiae but does not cleave the homologues
of eIF-4 gamma in vivo or in vitro.  Virology 1996, 220:109-118.
22. Davies DR: The structure and function of the aspartic protei-
nases.  Annu Rev Biophys Biophys Chem 1990, 19:189-215.
23. Shoeman RL, Honer B, Stoller TJ, Kesselmeier C, Miedel MC, Traub
P, Graves MC: Human immunodeficiency virus type 1 pro-
tease cleaves the intermediate filament proteins vimentin,
desmin, and glial fibrillary acidic protein.  Proc Natl Acad Sci U S
A 1990, 87:6336-6340.
24. Tomasselli AG, Hui JO, Adams L, Chosay J, Lowery D, Greenberg B,
Yem A, Deibl MR, Zurcher-Neely H, Heinrikson RL: Actin, tro-
ponin C, Alzheimer amyloid precursor protein and pro-
interleukin 1 beta as substrates of the protease from human
immunodeficiency virus.  J Biol Chem 1991, 266:14548-14553.
25. Wallin M, Deinum J, Goobar L, Danielson UH: Proteolytic cleav-
age of microtubule-associated proteins by retroviral protei-
nases.  J Gen Virol 1990, 71:1985-1991.
26. Strack PR, Frey MW, Rizzo CJ, Cordova B, George HJ, Meade R, Ho
SP, Corman J, Tritch R, Korant BD: Apoptosis mediated by HIV
protease is preceded by cleavage of Bcl-2.  Proc Natl Acad Sci U
S A 1996, 93:9571-9576.
27. Riviere Y, Blank V, Kourilsky P, Israel A: Processing of the precur-
sor of NF-kappa B by the HIV-1 protease during acute infec-
tion.  Nature 1991, 350:625-626.
28. Jin C, Reed JC: Yeast and Apoptosis.  Nat Rev Mol Cell Biol 2002,
3:453-459.
29. Rodes B, Toro C, Sheldon JA, Jimenez V, Mansinho K, Soriano V:
High rate of proV47A selection in HIV-2 patients failing lopi-
navir-based HAART.  AIDS 2006, 20:127-129.
30. Guyader M, Emerman M, Sonigo P, Clavel F, Montagnier L, Alizon M:
Genome organization and transactivation of the human
immunodeficiency virus type 2.  Nature 1987, 326:662-669.
31. EUROSCARF   [http://web.uni-frankfurt.de/fb15/mikro/euroscarf/]
32. Gietz RD, Woods RA: Yeast transformation by the LiAc/SS
Carrier DNA/PEG method.  Methods Mol Biol 2006, 313:107-120.
33. Garrido F, Banerjee UC, Chisti Y, Moo-Young M: Disruption of a
recombinant yeast for the release of beta-galactosidase.
Bioseparation 1994, 4:319-328.
34. Rittenhouse J, Turon MC, Helfrich RJ, Albrecht KS, Weigl D, Simmer
RL, Mordini F, Erickson J, Kohlbrenner WE: Affinity purification of
HIV-1 and HIV-2 proteases from recombinant E. coli strains
using pepstatin-agarose.  Biochem Biophys Res Commun 1990,
171:60-66.